People · Operator
Named in public records as an officer, director or promoter · active 2008–2020 · Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. | — | Pharmaceuticals | Series D+ | $527.4M | $2.4B | 2018 |
| Luxtera Inc | — | Other Technology | Series B | $91.8M | $1.1B | 2008 |
Andrew Rappaport at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Rappaport on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Forest Baskett | 1 | 15 |
| Greg Young | 1 | 8 |
| John Oxaal | 1 | 7 |
| Rohini Chakravarthy | 1 | 7 |
| Frank McCormick | 1 | 7 |
| Ian Clark | 1 | 5 |
| Andy Rappaport | 1 | 4 |
| Tom Foody | 1 | 3 |
| Marina Bozilenko | 1 | 3 |
| Gorjan Hrustanovic | 1 | 3 |
| Cynthia Butitta | 1 | 3 |
| Cyrus Harmon | 1 | 2 |
| Alex Dickinson | 1 | 2 |
| Andrei Manoliu | 1 | 2 |
| Sean Bohen | 1 | 2 |
| Lawrence Fritz | 1 | 2 |
| Eli Yablonovitch | 1 | 2 |
| Graham Walmsley | 1 | 2 |
| David Myles | 1 | 2 |
| Seamus Daly | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.